Announced Mon, 29 Sept · 17:29 IST

Solara Active Pharma Sciences Limited has submitted the Exchange a copy Scrutinizer's report and Voting Results of the 8th Annual General Meeting held on September 25, 2025

Board & Shareholder Meetings View source PDF

SOLARA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Solara Active Pharma Sciences held its 8th AGM on September 25, 2025, via video conferencing from 10:30 AM to 11:02 AM, with a total of 73,100 shareholders on record. All six resolutions were passed with overwhelming majority. These included adoption of audited financial statements for FY25 (99.9996% in favor), appointment of Mr. Mohan Muthunarayanan as Executive Director (99.98%) and Mr. Manish Gupta as Non-Executive Director (99.99%), ratification of Cost Auditor remuneration for FY26 (99.97%), and appointment of Secretarial Auditor (99.99%). A key resolution approving material related party transactions with Strides Pharma Science Limited worth up to Rs. 400 crores was also passed with 99.87% support, though promoter group shares (1.07 crore) were excluded from voting as they are related parties. The scrutinizer, Preetham Hebbar & Co., confirmed the voting process was conducted fairly in line with SEBI and Companies Act rules.

Likely market impact

All AGM resolutions were approved with near-unanimous support, indicating strong shareholder confidence in management. The approval of up to Rs. 400 crore in related party transactions with Strides Pharma is notable — investors should monitor these transactions for related-party governance, though promoter abstention from voting on that specific item is a standard compliance practice.